Business

Amneal Pharmaceuticals and Impax Laboratories have announced that the companies will merge, with the new company to be called Amneal Pharmaceuticals, Inc. The merger is expected to be complete by mid-2018. OINDPs marketed by Amneal… Read more . . .

Aegis Therapeutics says that it has developed an intranasal hydromorphone for the treatment of acute pain and is making the formulation available for license. According to the company, the formulation, which is based on the… Read more . . .

Engage Therapeutics has closed a $23 million Series A financing round led by TPG Biotech that will fund a Phase 2b clinical trial of an inhaled alprazolam for the treatment of acute epileptic seizures. Alexza… Read more . . .

Galen US has acquired US rights to Alexza Pharmaceuticals’ Adasuve inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar I. Adasuve was approved by the FDA in December 2012 for use… Read more . . .

4D Molecular Therapeutics (4DMT) has received $3 million from Cystic Fibrosis Foundation Therapeutics (CFFT) for development of 4D-710, an aerosolized adeno-associated virus (AAV) gene therapy vector that will deliver a functional copy of the CFTR… Read more . . .

The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded a grant worth up to $63 million to Emergent BioSolutions for development of a single-use stabilized isoamyl nitrite… Read more . . .

Insmed has closed a public offering of common stock that generated net proceeds of ~$377.7 million, the company said. The proceeds will be used in large part for continued development, regulatory submissions, and potential commercialization… Read more . . .

Pulmatrix has announced a licensing agreement with Vectura for US development of Pulmatrix’s PUR0200 dry powder tiotropium formulation for the treatment of COPD. Vectura will pay Pulmatrix a $1 million “technology access fee” on achievement… Read more . . .

According to Pulmatrix, the Cystic Fibrosis Foundation Therapeutics (CFFT) will provide funds to support non-clinical development of PUR1900, an itraconazole DPI, for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis and asthma patients.… Read more . . .

Ascend Therapeutics is now promoting Egalet’s Sprix ketorolac tromethamine nasal spray for the treatment of moderate-to-moderately severe pain to women’s healthcare providers in the US, Egalet said. According to Egalet, the companies signed the agreement… Read more . . .